It was a privilege to meet Alexandre Lourenço, President of the Portuguese Association of Hospital Managers, at the ECCO 2019 European Cancer Summit in Brussels to discuss his expert opinion on how we can introduce novel therapies into use in a sustainable way.
1. To what extent is access to innovative cancer treatments limited in Portugal and is there a similar issue in other European nations? (0:08)
2. Is restricted access to some cancer treatments resulting in poor patient outcomes, increased morbidity and earlier deaths? (0:44)
3. Treatments such as chimeric antigen receptor (CAR) T-cells are highly effective in the treatment of some cancers. Could access to this and other novel treatments be increased through increased funding and/or improved technologies? (1:19)
4. Can you describe the key aims of the Primary Care P4P initiative in Portugal and how it could improve primary care in cancer? (1:50)
5. The Association of European Cancer Leagues (ECL) Access to Medicines Taskforce and other organisations aim to improve the availability of new cancer treatments. What progress have these organisations made towards this goal and what remains to be done? (3:00)
Alexandre Lourenço has no conflicts of interest to declare in relation to this video.
Filmed in partnership with the European CanCer Organisation at the ECCO 2019 European Cancer Summit in Brussels, Belgium.
Share this Video
Related Videos In Policy
Stefan Gijssels, Eureopean Cancer Summit 2020 – The Beating Cancer Plan
touchONCOLOGY means Stefan Gijssels at the European Cancer Summit 2020 to discuss the Beating Cancer Plan and key highlights and outcomes from this year’s meeting. Questions How do you expect the cancer burden in Europe to change in the coming years? What are the aims and main components of the Beating Cancer Plan? What initiatives […]
Françoise Meunier, European Cancer Summit 2020 – Financial Toxicity and the ‘Right to be Forgotten’
Dr Françoise Meunier, Vice President of the Federation of European Academies of Medicine, joins touchONCOLOGY to discuss financial toxicity in patients with cancer and progress made with the “Right to be Forgotten” resolution made at the European Cancer Summit in 2018. Questions What does the term ‘financial toxicity’ mean, and what does it mean for […]
Daniel Kelly, European Cancer Summit 2020 – HPV Action Network
touchONCOLOGY joins Prof. Daniel Kelly to discuss the aims and scope of the European Cancer Organisation HPV Action Network. Questions What are the aims of the HPV Action Network? How can HPV-associated cancers be reduced and why is this resolution important? Could you tell us about the European Cancer Organisation’s recent action plan and report, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!